beta

AFMD

Affimed N.V.

Afmd

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-07-2018 08-08-2018 05-15-2018 03-20-2018 11-07-2017 08-01-2017 05-17-2017
Actual EPS -0.22 -0.16 -0.18 -0.16 -0.21 -0.2 -0.2
Consensus EPS -0.17 -0.17 -0.18 -0.16 -0.21 -0.22 -0.24
Estimated EPS -0.17 -0.17 -0.18 -0.16 -0.21 -0.22 -0.24
Number of Estimates 3 3 3 3 5 4 4
EPS Surprise -$0.05 $0.01 $0.02 $0.04

Stats

Summary

Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology to fight tumor cells.

Market Cap: 61.4 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.affimed.com

Shares Outstanding: 44.7 Million

Float: 44.7 Million

Dividend: 0.0 (0.0%)

Beta: 3.29047

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 315 Thousand

Ethical Flags

Animal testing

Longest drawdown: 857 trading days

From: 2015-07-17 To: 2018-12-11

Lowest Point:

Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial

via: SeekingAlpha at 2018-12-12 10:29:51:000

As the previous article provided a broad overview of Affimed and the opportunity for investors , this follow-up will concentrate almost exclusively on takeaways from the AFM13-focused R&D Day. Extreme market weakness on the R&D day overshadowed a positive event for Affimed ( AFMD ) … read more...

Affimed: Promising, Undervalued Immunotherapy Play With Multiple Catalysts Ahead

via: SeekingAlpha at 2018-12-06 17:52:37:000

Affimed is an undervalued immunotherapy company that has attracted warranted attention from several smart players in biotech In the world of immunotherapy where finetuning and engaging the human immune system to better recognize bad actors such as cancer, superior patient outcomes are on t… read more...

Affimed: Promising, Undervalued Immunotherapy Play With Multiple Catalysts Ahead

via: SeekingAlpha at 2018-12-06 17:52:37:000

Affimed is an undervalued immunotherapy company that has attracted warranted attention from several smart players in biotech In the world of immunotherapy where finetuning and engaging the human immune system to better recognize bad actors such as cancer, superior patient outcomes are on t… read more...

Affimed: Promising, Undervalued Immunotherapy Play With Multiple Catalysts Ahead

via: SeekingAlpha at 2018-12-06 17:52:37:000

Affimed is an undervalued immunotherapy company that has attracted warranted attention from several smart players in biotech In the world of immunotherapy where finetuning and engaging the human immune system to better recognize bad actors such as cancer, superior patient outcomes are on t… read more...

VIPS, BZUN among premarket gainers

via: SeekingAlpha at 2018-12-03 09:25:27:000

Tesaro (NASDAQ: TSRO ) +59% on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more … read more...

VIPS, BZUN among premarket gainers

via: SeekingAlpha at 2018-12-03 09:25:27:000

Tesaro (NASDAQ: TSRO ) +59% on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more … read more...

VIPS, BZUN among premarket gainers

via: SeekingAlpha at 2018-12-03 09:25:27:000

Tesaro (NASDAQ: TSRO ) +59% on acquisition by Glaxo for $75. More news on: Tesaro, Global Blood Therapeutics, Hudson Technologies, Inc., Stocks on the move, , Read more … read more...

Affimed Clinical Hold Likely To Be Resolved Soon

via: SeekingAlpha at 2018-11-29 07:03:55:000

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (superior efficacy and safety, serve unmet needs, and have limited competition). Affimed ( AFMD ) is developing powerful engagers of the immune system for the treatment of c… read more...

Affimed Clinical Hold Likely To Be Resolved Soon

via: SeekingAlpha at 2018-11-29 07:03:55:000

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (superior efficacy and safety, serve unmet needs, and have limited competition). Affimed ( AFMD ) is developing powerful engagers of the immune system for the treatment of c… read more...

Affimed Clinical Hold Likely To Be Resolved Soon

via: SeekingAlpha at 2018-11-29 07:03:55:000

Preface Within my exclusive marketplace, The Formula , I look for assets that provide therapeutic differentiation (superior efficacy and safety, serve unmet needs, and have limited competition). Affimed ( AFMD ) is developing powerful engagers of the immune system for the treatment of c… read more...

Affimed Therapeutics (AFMD) CEO Adi Hoess on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 14:44:11:000

Start Time: 08:30 End Time: 09:14 Affimed Therapeutics (AFMD) Q3 2018 Earnings Conference Call November 07, 2018, 08:30 AM ET Executives Adi Hoess - CEO Florian Fischer - CFO Leila Alland - CMO Greg Gin - Head of IR Analysts Peter Lawson - SunTrust Robinson Humphrey … read more...

Affimed Therapeutics (AFMD) CEO Adi Hoess on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 14:44:11:000

Start Time: 08:30 End Time: 09:14 Affimed Therapeutics (AFMD) Q3 2018 Earnings Conference Call November 07, 2018, 08:30 AM ET Executives Adi Hoess - CEO Florian Fischer - CFO Leila Alland - CMO Greg Gin - Head of IR Analysts Peter Lawson - SunTrust Robinson Humphrey … read more...

Affimed Therapeutics (AFMD) CEO Adi Hoess on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-07 14:44:11:000

Start Time: 08:30 End Time: 09:14 Affimed Therapeutics (AFMD) Q3 2018 Earnings Conference Call November 07, 2018, 08:30 AM ET Executives Adi Hoess - CEO Florian Fischer - CFO Leila Alland - CMO Greg Gin - Head of IR Analysts Peter Lawson - SunTrust Robinson Humphrey … read more...

Affimed Therapeutics 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-07 10:17:48:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q3 earnings Read more … read more...

Affimed Therapeutics 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-07 10:17:48:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q3 earnings Read more … read more...

Affimed Therapeutics 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-11-07 10:17:48:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q3 earnings Read more … read more...

Affimed reports Q3 results

via: SeekingAlpha at 2018-11-07 07:32:37:000

Affimed (NASDAQ: AFMD ): Q3 GAAP EPS of -0.19. More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q3 results

via: SeekingAlpha at 2018-11-07 07:32:37:000

Affimed (NASDAQ: AFMD ): Q3 GAAP EPS of -0.19. More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q3 results

via: SeekingAlpha at 2018-11-07 07:32:37:000

Affimed (NASDAQ: AFMD ): Q3 GAAP EPS of -0.19. More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

A Company In Decline? The Case For/Against Affimed After Bad News

via: SeekingAlpha at 2018-10-14 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy has become one o… read more...

A Company In Decline? The Case For/Against Affimed After Bad News

via: SeekingAlpha at 2018-10-14 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy has become one o… read more...

A Company In Decline? The Case For/Against Affimed After Bad News

via: SeekingAlpha at 2018-10-14 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy has become one o… read more...

Investment Thesis Of Forty Seven

via: SeekingAlpha at 2018-10-11 12:37:40:000

C ompany overview Forty Seven, Inc. ( FTSV ) is a clinical stage biotech company headquartered in Menlo Park, CA. This company completed its IPO in June 2018 by raising $116 million with price of $16.00 per share. The company is focusing on immune-therapy field by developing novel che… read more...

Investment Thesis Of Forty Seven

via: SeekingAlpha at 2018-10-11 12:37:40:000

C ompany overview Forty Seven, Inc. ( FTSV ) is a clinical stage biotech company headquartered in Menlo Park, CA. This company completed its IPO in June 2018 by raising $116 million with price of $16.00 per share. The company is focusing on immune-therapy field by developing novel che… read more...

Investment Thesis Of Forty Seven

via: SeekingAlpha at 2018-10-11 12:37:40:000

C ompany overview Forty Seven, Inc. ( FTSV ) is a clinical stage biotech company headquartered in Menlo Park, CA. This company completed its IPO in June 2018 by raising $116 million with price of $16.00 per share. The company is focusing on immune-therapy field by developing novel che… read more...

Biotech Analysis Central Pharma News: Menlo's Failure, Trevena's Documents, Affimed Halts Studies

via: SeekingAlpha at 2018-10-10 10:20:35:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Menlo Suffers Second Major Blow After Drug Fails Another Mid-Stage Study News: Recently, Menlo Therapeutics ( MNLO ) announced that it had failed its … read more...

Your Daily Pharma Scoop: Adamas GOCOVRI Shows Positive Effect, Affimed Down On Clinical Hold

via: SeekingAlpha at 2018-10-09 13:47:50:000

Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths … read more...

Premarket Losers as of 9:05 am (10/9/2018)

via: SeekingAlpha at 2018-10-09 09:11:42:000

TRVN -63% ahead of FDA Ad Com for pain med oliceridine. More news on: Trevena, Inc., Affimed Therapeutics, Blackbaud, Inc., Stocks on the move, Top stock market news, , Read more … read more...

Stocks making the biggest move premarket: TSLA, PZZA, MSFT, WMT & more

via: CNBC at 2018-10-09 08:21:00:000

No summary available. read more...

Cancer Research Highlight: Affimed Has A Major Setback; Can They Recover?

via: SeekingAlpha at 2018-10-09 08:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Affimed Therapeutics ( AFMD ) … read more...

After-hours buzz: TSLA, EW & more

via: CNBC at 2018-10-08 17:05:00:000

No summary available. read more...

Affimed suspends clinical studies of blood cancer candidate AFM11 after adverse events

via: SeekingAlpha at 2018-10-08 16:38:51:000

Affimed N.V. (NASDAQ: AFMD ) has placed its AFM11 program on clinical hold following three serious adverse events (SAEs), one death in a Phase 1 ALL study and two life-threatening events in a Phase 1 NHL study. More news on: Affimed Therapeutics, Healthcare stocks news, Stocks on the mov… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

Small Caps Are Rising, Biotechs Can't Be Far Behind

via: SeekingAlpha at 2018-09-05 13:31:02:000

Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and… read more...

Small Caps Are Rising, Biotechs Can't Be Far Behind

via: SeekingAlpha at 2018-09-05 13:31:02:000

Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and… read more...

Small Caps Are Rising, Biotechs Can't Be Far Behind

via: SeekingAlpha at 2018-09-05 13:31:02:000

Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and… read more...

Affimed Therapeutics: Continued Upside Ahead

via: SeekingAlpha at 2018-08-29 23:53:57:000

Shares of German biotech Affimed Therapeutics (AFMD) have risen by around 220% since my February article came out stating that data would finally trump poor execution in 2018. However, one catalyst I failed to spend time on was the possibility of management finally inking a partnership with … read more...

Affimed Therapeutics: Continued Upside Ahead

via: SeekingAlpha at 2018-08-29 23:53:57:000

Shares of German biotech Affimed Therapeutics (AFMD) have risen by around 220% since my February article came out stating that data would finally trump poor execution in 2018. However, one catalyst I failed to spend time on was the possibility of management finally inking a partnership with … read more...

Affimed Therapeutics: Continued Upside Ahead

via: SeekingAlpha at 2018-08-29 23:53:57:000

Shares of German biotech Affimed Therapeutics (AFMD) have risen by around 220% since my February article came out stating that data would finally trump poor execution in 2018. However, one catalyst I failed to spend time on was the possibility of management finally inking a partnership with … read more...

After Hours Gainers / Losers (08/29/2018)

via: SeekingAlpha at 2018-08-29 17:36:00:000

Top Gainers: GES +10.9% . TLYS +9.4% . SMTC +8.4% . ZYNE +3.2% . More news on: Guess? Inc., Tilly's, Inc., Semtech Corporation, Stocks on the move, , Read more … read more...

Your Daily Pharma Scoop: ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozempic Succeeds

via: SeekingAlpha at 2018-08-29 13:18:40:000

Stocks in News: ESPR Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study Discussion: Positive top-line results from the pivotal Phase 3 trial of Esperions ( ESPR ) bempedoic acid/ezetimibe combination pill study ( 1… read more...

Midday Gainers / Losers (08/29/2018)

via: SeekingAlpha at 2018-08-29 12:48:19:000

Gainers: OPNT +50% . IGC +40% . GKOS +36% . EVFM +26% . IPAS +27% . SPHS +27% . AFMD +25% . JMU +19% . YRD +17% . ZYNE +17% . More news on: Opiant Pharmaceuticals, Inc., India Globalization Capital, Inc, Glaukos, Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (08/29/2018)

via: SeekingAlpha at 2018-08-29 09:24:20:000

OPNT +79% on EBS takeout of Adapt Pharma. More news on: Opiant Pharmaceuticals, Inc., Glaukos, India Globalization Capital, Inc, Stocks on the move, , Read more … read more...

After Hours Gainers / Losers (08/28/2018)

via: SeekingAlpha at 2018-08-28 17:35:20:000

Top Gainers: TLRY +13.9% . SCVL +8.5%. CRON +6.6% . AVNW +4.8% . AFMD +4.1% . More news on: Tilray, Inc., Shoe Carnival, Inc., Cronos Group, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (08/28/2018)

via: SeekingAlpha at 2018-08-28 12:45:53:000

Gainers: AFMD +220% . ATAI +43% . STAF +30% . ASFI +26% . BRKS +27% . VVPR +19% . DSW +18% . CVM +17% . BILI +16% . ABIL +15% . More news on: Affimed Therapeutics, ATA Inc., Staffing 360 Solutions, Inc., Stocks on the move, , Read more … read more...

Premarket Gainers as of 9:05 am (08/28/2018)

via: SeekingAlpha at 2018-08-28 09:16:15:000

AFMD +169% with Genentech to develop cancer therapies in potential multi-billion dollar deal. More news on: Affimed Therapeutics, Staffing 360 Solutions, Inc., DSW Inc., Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-28 08:10:04:000

Wright Medical Group (NASDAQ: WMGI ) upgraded to Buy with a $30 (12% upside) price target at Needham citing upside from Cartiva acquisition. Shares down 3% premarket on equity offering to finance the transaction. More news on: Wright Medical Group, Inc., Fresenius Medical Care … read more...

Affimed Receives A Massive Hail Mary Collaboration From Roche

via: SeekingAlpha at 2018-08-27 22:41:45:000

In after hours trade on Monday, Affimed N.V. ( AFMD ) announced a large collaboration deal with Roche ( OTCQX:RHHBY ). Shares of Affimed surged as much as 140% on this news. Both companies are to collaborate to develop a host of immunotherapies to treat a host of different cancers. Thi… read more...

After Hours Gainers / Losers (08/27/2018)

via: SeekingAlpha at 2018-08-27 17:38:51:000

Top Gainers: AFMD +112.3% . BRKS +15.7% . HEI +5.8% . LSCC +5.4% . LEVB +4.1% . More news on: Affimed Therapeutics, Brooks Automation, Inc., HEICO Corporation, Stocks on the move, , Read more … read more...

Affimed teams up with Genentech to develop cancer therapies in potential multi-billion dollar deal; shares up 113% after hours

via: SeekingAlpha at 2018-08-27 16:44:42:000

Affimed N.V. (NASDAQ: AFMD ) inks a collaboration agreement with Roche ( OTCQX:RHHBY ) unit Genentech aimed at developing novel NK cell engager-based therapies for a range of cancers leveraging Affimed's proprietary Redirected Optimized Cell Killing (ROCK) platform. More news on: Affimed… read more...

Affimed Therapeutics (AFMD) CEO Adi Hoess on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-08 17:30:48:000

Affimed Therapeutics (AFMD) Q2 2018 Results Earnings Conference Call August 07, 2018 08:30 AM ET Executives Greg Gin - Head of Investor Relations Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Presentation Operator Good day, and welcome to… read more...

Affimed Therapeutics (AFMD) CEO Adi Hoess on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-08 17:30:48:000

Affimed Therapeutics (AFMD) Q2 2018 Results Earnings Conference Call August 07, 2018 08:30 AM ET Executives Greg Gin - Head of Investor Relations Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Presentation Operator Good day, and welcome to… read more...

Affimed Therapeutics (AFMD) CEO Adi Hoess on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-08 17:30:48:000

Affimed Therapeutics (AFMD) Q2 2018 Results Earnings Conference Call August 07, 2018 08:30 AM ET Executives Greg Gin - Head of Investor Relations Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Presentation Operator Good day, and welcome to… read more...

Affimed beats by Euro0.02, misses on revenue

via: SeekingAlpha at 2018-08-08 07:35:42:000

Affimed (NASDAQ: AFMD ): Q2 EPS of -0.13 beats by 0.02 . More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed beats by Euro0.02, misses on revenue

via: SeekingAlpha at 2018-08-08 07:35:42:000

Affimed (NASDAQ: AFMD ): Q2 EPS of -0.13 beats by 0.02 . More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed beats by Euro0.02, misses on revenue

via: SeekingAlpha at 2018-08-08 07:35:42:000

Affimed (NASDAQ: AFMD ): Q2 EPS of -0.13 beats by 0.02 . More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Midday Gainers / Losers (06/15/2018)

via: SeekingAlpha at 2018-06-15 12:36:26:000

Gainers: CLPS +34% . GOOS +27% . NDRA +24% . BAK +19% . TPIV +19% . VSTM +16% . CFRX +15% . NETE +14% . TCI +14% . NEWA +13% . More news on: CLPS, Inc, Canada Goose Holdings, Endra Life Sciences Inc, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (6/15/2018)

via: SeekingAlpha at 2018-06-15 09:14:23:000

ACHV -28% on continued sell off. More news on: Achieve Life Sciences, Inc., Affimed Therapeutics, Destination Maternity Corporation, Stocks on the move, , Read more … read more...

Affimed up 11%

via: SeekingAlpha at 2018-06-14 11:23:39:000

Thinly traded micro cap Affimed Therapeutics ( AFMD +11.1% ) is up more than a 5x surge in volume. Shares have doubled this year. More news on: Affimed Therapeutics, Healthcare stocks news, Stocks on the move, Read more … read more...

Three Biotechs With Upcoming Data At Conferences

via: SeekingAlpha at 2018-06-11 14:19:22:000

Written by Dan Cohen and Scott Matusow Cytokinetics ( CYTK ) looks to turn around their fortunes following last years unsuccessful readout of Tirasemtiv in ALS. As the lead investigator had highlighted in his presentation of the data, 65.8% of patients were still in the active … read more...

Three Biotechs With Upcoming Data At Conferences

via: SeekingAlpha at 2018-06-11 14:19:22:000

Written by Dan Cohen and Scott Matusow Cytokinetics ( CYTK ) looks to turn around their fortunes following last years unsuccessful readout of Tirasemtiv in ALS. As the lead investigator had highlighted in his presentation of the data, 65.8% of patients were still in the active … read more...

Three Biotechs With Upcoming Data At Conferences

via: SeekingAlpha at 2018-06-11 14:19:22:000

Written by Dan Cohen and Scott Matusow Cytokinetics ( CYTK ) looks to turn around their fortunes following last years unsuccessful readout of Tirasemtiv in ALS. As the lead investigator had highlighted in his presentation of the data, 65.8% of patients were still in the active … read more...

Week 22 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-27 01:30:59:000

Breakout Forecast Selections for Week 22: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 73 last week down to a value of 57 this week. The all time low for the positive momentum selection gauge is… read more...

Week 22 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-27 01:30:59:000

Breakout Forecast Selections for Week 22: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 73 last week down to a value of 57 this week. The all time low for the positive momentum selection gauge is… read more...

Week 22 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-27 01:30:59:000

Breakout Forecast Selections for Week 22: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 73 last week down to a value of 57 this week. The all time low for the positive momentum selection gauge is… read more...

Week 22 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-27 01:30:59:000

Breakout Forecast Selections for Week 22: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 73 last week down to a value of 57 this week. The all time low for the positive momentum selection gauge is… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

Affimed Therapeutics' (AFMD) CEO, Adi Hoess on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:53:10:000

Affimed Therapeutics (AFMD) Q1 2018 Earnings Conference Call May 15, 2018 9:00 am ET Executives Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Anca Alexandru - Head of Communications Analysts Do Kim - BMO… read more...

Affimed Therapeutics' (AFMD) CEO, Adi Hoess on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:53:10:000

Affimed Therapeutics (AFMD) Q1 2018 Earnings Conference Call May 15, 2018 9:00 am ET Executives Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Anca Alexandru - Head of Communications Analysts Do Kim - BMO… read more...

Affimed Therapeutics' (AFMD) CEO, Adi Hoess on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:53:10:000

Affimed Therapeutics (AFMD) Q1 2018 Earnings Conference Call May 15, 2018 9:00 am ET Executives Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Anca Alexandru - Head of Communications Analysts Do Kim - BMO… read more...

Affimed Therapeutics' (AFMD) CEO, Adi Hoess on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:53:10:000

Affimed Therapeutics (AFMD) Q1 2018 Earnings Conference Call May 15, 2018 9:00 am ET Executives Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Anca Alexandru - Head of Communications Analysts Do Kim - BMO… read more...

Affimed Therapeutics' (AFMD) CEO, Adi Hoess on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:53:10:000

Affimed Therapeutics (AFMD) Q1 2018 Earnings Conference Call May 15, 2018 9:00 am ET Executives Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Anca Alexandru - Head of Communications Analysts Do Kim - BMO… read more...

Affimed Therapeutics' (AFMD) CEO, Adi Hoess on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-15 13:53:10:000

Affimed Therapeutics (AFMD) Q1 2018 Earnings Conference Call May 15, 2018 9:00 am ET Executives Adi Hoess - Chief Executive Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Anca Alexandru - Head of Communications Analysts Do Kim - BMO… read more...

Affimed Therapeutics 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-15 10:47:27:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q1 earnings Read more … read more...

Affimed Therapeutics 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-15 10:47:27:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q1 earnings Read more … read more...

Affimed Therapeutics 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-15 10:47:27:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q1 earnings Read more … read more...

Affimed Therapeutics 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-15 10:47:27:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q1 earnings Read more … read more...

Affimed Therapeutics 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-15 10:47:27:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q1 earnings Read more … read more...

Affimed Therapeutics 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-15 10:47:27:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2018 Q1 earnings Read more … read more...

Affimed reports Q1 results

via: SeekingAlpha at 2018-05-15 07:52:52:000

Affimed (NASDAQ: AFMD ): Q1 EPS of -0.15 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q1 results

via: SeekingAlpha at 2018-05-15 07:52:52:000

Affimed (NASDAQ: AFMD ): Q1 EPS of -0.15 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q1 results

via: SeekingAlpha at 2018-05-15 07:52:52:000

Affimed (NASDAQ: AFMD ): Q1 EPS of -0.15 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q1 results

via: SeekingAlpha at 2018-05-15 07:52:52:000

Affimed (NASDAQ: AFMD ): Q1 EPS of -0.15 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q1 results

via: SeekingAlpha at 2018-05-15 07:52:52:000

Affimed (NASDAQ: AFMD ): Q1 EPS of -0.15 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports Q1 results

via: SeekingAlpha at 2018-05-15 07:52:52:000

Affimed (NASDAQ: AFMD ): Q1 EPS of -0.15 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Week 19 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-06 01:42:37:000

Breakout Forecast Selections for Week 19: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 52 last week up to a value of 61 this week. The all time low for the positive momentum selection gauge… read more...

Week 19 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-06 01:42:37:000

Breakout Forecast Selections for Week 19: Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium) moving from a value of 52 last week up to a value of 61 this week. The all time low for the positive momentum selection gauge… read more...

Week 16 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-04-15 14:29:27:000

Breakout Forecast Selections for Week 16: Market conditions continue with extreme volatility. The positive momentum gauge has finally moved into the yellow from a value of 14 to a value of 40. Volatility in the market remains at high levels and we have not been above the midpoint value of 60… read more...

Week 16 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-04-15 14:29:27:000

Breakout Forecast Selections for Week 16: Market conditions continue with extreme volatility. The positive momentum gauge has finally moved into the yellow from a value of 14 to a value of 40. Volatility in the market remains at high levels and we have not been above the midpoint value of 60… read more...

Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-20 14:58:11:000

Affimed Therapeutics (AFMD) Q4 2017 Earnings Conference Call March 20, 2018 08:30 ET Executives Anca Alexandru - Head-Communications Adi Hoess - CEO Florian Fischer - CFO Analysts Presentation Operator Good day, welcome to the Affimed Fourth Quarter and Year End 201… read more...

Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-20 14:58:11:000

Affimed Therapeutics (AFMD) Q4 2017 Earnings Conference Call March 20, 2018 08:30 ET Executives Anca Alexandru - Head-Communications Adi Hoess - CEO Florian Fischer - CFO Analysts Presentation Operator Good day, welcome to the Affimed Fourth Quarter and Year End 201… read more...

Affimed reports FY results

via: SeekingAlpha at 2018-03-20 07:35:05:000

Affimed (NASDAQ: AFMD ): FY EPS of -0.69 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Affimed reports FY results

via: SeekingAlpha at 2018-03-20 07:35:05:000

Affimed (NASDAQ: AFMD ): FY EPS of -0.69 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-03-19 17:30:54:000

AFMD , DLTH , PLCE For Seeking Alpha's full earnings season calendar, click here . More news on: Affimed Therapeutics, Duluth Holdings, The Children's Place Retail Stores, Inc., Earnings news and commentary, , , read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-03-19 17:30:54:000

AFMD , DLTH , PLCE For Seeking Alpha's full earnings season calendar, click here . More news on: Affimed Therapeutics, Duluth Holdings, The Children's Place Retail Stores, Inc., Earnings news and commentary, , , read more...

Affimed (AFMD) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-15 13:21:11:000

The following slide deck was published by Affimed Therapeutics in conjunction with this Read more … read more...

Affimed (AFMD) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-03-15 13:21:11:000

The following slide deck was published by Affimed Therapeutics in conjunction with this Read more … read more...

Midday Gainers / Losers (2/13/2018)

via: SeekingAlpha at 2018-02-13 12:50:48:000

Gainers: CATB +56% . AQMS +30% . GNC +30% . TYHT +26% . OPNT +23% . OSN +22% . CHGG +18% . AXON +15% . VECO +15% . UAA +15% . More news on: Catabasis Pharmaceuticals, Aqua Metals, GNC Holdings, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (2/13/2018)

via: SeekingAlpha at 2018-02-13 12:50:48:000

Gainers: CATB +56% . AQMS +30% . GNC +30% . TYHT +26% . OPNT +23% . OSN +22% . CHGG +18% . AXON +15% . VECO +15% . UAA +15% . More news on: Catabasis Pharmaceuticals, Aqua Metals, GNC Holdings, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (2/13/2018)

via: SeekingAlpha at 2018-02-13 12:50:48:000

Gainers: CATB +56% . AQMS +30% . GNC +30% . TYHT +26% . OPNT +23% . OSN +22% . CHGG +18% . AXON +15% . VECO +15% . UAA +15% . More news on: Catabasis Pharmaceuticals, Aqua Metals, GNC Holdings, Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (2/13/2018)

via: SeekingAlpha at 2018-02-13 09:17:30:000

DARE -33% on announcing public offering of common stock. More news on: Dare Bioscience, Inc., Helios and Matheson Analytics, Inc., Pacific Biosciences of California, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (2/13/2018)

via: SeekingAlpha at 2018-02-13 09:17:30:000

DARE -33% on announcing public offering of common stock. More news on: Dare Bioscience, Inc., Helios and Matheson Analytics, Inc., Pacific Biosciences of California, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (2/13/2018)

via: SeekingAlpha at 2018-02-13 09:17:30:000

DARE -33% on announcing public offering of common stock. More news on: Dare Bioscience, Inc., Helios and Matheson Analytics, Inc., Pacific Biosciences of California, Stocks on the move, , Read more … read more...

After Hours Gainers / Losers (2/12/2018)

via: SeekingAlpha at 2018-02-12 17:38:30:000

Top gainers: KDMN +15.7% . VIPS +10.3% . VECO +6.6% . SREV +6.1% . Top losers: AFMD -6.1% . G -4.3% . NVTA -4.3% . FENG -3.5% . TER -2.0% . More news on: Kadmon Holdings, Vipshop Holdings, Veeco Instruments Inc., Stocks on the move, Dividend news, , read more...

After Hours Gainers / Losers (2/12/2018)

via: SeekingAlpha at 2018-02-12 17:38:30:000

Top gainers: KDMN +15.7% . VIPS +10.3% . VECO +6.6% . SREV +6.1% . Top losers: AFMD -6.1% . G -4.3% . NVTA -4.3% . FENG -3.5% . TER -2.0% . More news on: Kadmon Holdings, Vipshop Holdings, Veeco Instruments Inc., Stocks on the move, Dividend news, , read more...

After Hours Gainers / Losers (2/12/2018)

via: SeekingAlpha at 2018-02-12 17:38:30:000

Top gainers: KDMN +15.7% . VIPS +10.3% . VECO +6.6% . SREV +6.1% . Top losers: AFMD -6.1% . G -4.3% . NVTA -4.3% . FENG -3.5% . TER -2.0% . More news on: Kadmon Holdings, Vipshop Holdings, Veeco Instruments Inc., Stocks on the move, Dividend news, , read more...

Finding Biotech Value In All-Time Highs

via: SeekingAlpha at 2018-02-10 00:56:27:000

Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies ([[SAGE]], [[FATE]], [[PIRS]], [[CBAY]], [[SGMO]], etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes… read more...

Finding Biotech Value In All-Time Highs

via: SeekingAlpha at 2018-02-10 00:56:27:000

Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies ([[SAGE]], [[FATE]], [[PIRS]], [[CBAY]], [[SGMO]], etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes… read more...

Finding Biotech Value In All-Time Highs

via: SeekingAlpha at 2018-02-10 00:56:27:000

Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies ([[SAGE]], [[FATE]], [[PIRS]], [[CBAY]], [[SGMO]], etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes… read more...

Finding Biotech Value In All-Time Highs

via: SeekingAlpha at 2018-02-10 00:56:27:000

Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies ([[SAGE]], [[FATE]], [[PIRS]], [[CBAY]], [[SGMO]], etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes… read more...

Premarket Losers as of 9:05 am (2/6/2018)

via: SeekingAlpha at 2018-02-06 09:12:21:000

INPX -30% . More news on: Inpixon, Cirrus Logic, Inc., Meridian Waste Solutions, Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (2/6/2018)

via: SeekingAlpha at 2018-02-06 09:12:21:000

INPX -30% . More news on: Inpixon, Cirrus Logic, Inc., Meridian Waste Solutions, Inc., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (2/6/2018)

via: SeekingAlpha at 2018-02-06 09:12:21:000

INPX -30% . More news on: Inpixon, Cirrus Logic, Inc., Meridian Waste Solutions, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (2/5/2018)

via: SeekingAlpha at 2018-02-05 12:44:32:000

Gainers: AFMD +33% . EYES +20% . CHCI +18% . IPWR +12% . ARMO +13% . ENPH +12% . APRI +11% . NGVC +10% . GRVY +10% . OGEN +9% . More news on: Affimed Therapeutics, Second Sight Medical Products, Comstock Homebuilding Companies, Inc., Stocks on the move, … read more...

Midday Gainers / Losers (2/5/2018)

via: SeekingAlpha at 2018-02-05 12:44:32:000

Gainers: AFMD +33% . EYES +20% . CHCI +18% . IPWR +12% . ARMO +13% . ENPH +12% . APRI +11% . NGVC +10% . GRVY +10% . OGEN +9% . More news on: Affimed Therapeutics, Second Sight Medical Products, Comstock Homebuilding Companies, Inc., Stocks on the move, … read more...

Midday Gainers / Losers (2/5/2018)

via: SeekingAlpha at 2018-02-05 12:44:32:000

Gainers: AFMD +33% . EYES +20% . CHCI +18% . IPWR +12% . ARMO +13% . ENPH +12% . APRI +11% . NGVC +10% . GRVY +10% . OGEN +9% . More news on: Affimed Therapeutics, Second Sight Medical Products, Comstock Homebuilding Companies, Inc., Stocks on the move, … read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018

via: SeekingAlpha at 2018-02-02 06:43:19:000

Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...

Affimed Therapeutics' Data Will Finally Trump Execution In 2018

via: SeekingAlpha at 2018-02-01 16:15:49:000

Shares of German biotech firm Affimed Therapeutics ( AFMD ) have lost close to 70% of their value over the past three years and been a serial disappointment to investors. As I 'm looking at the ticker now it 's traded over 20 times average daily volume and appears to be filling the recent g… read more...

Affimed Therapeutics' Data Will Finally Trump Execution In 2018

via: SeekingAlpha at 2018-02-01 16:15:49:000

Shares of German biotech firm Affimed Therapeutics ( AFMD ) have lost close to 70% of their value over the past three years and been a serial disappointment to investors. As I 'm looking at the ticker now it 's traded over 20 times average daily volume and appears to be filling the recent g… read more...

Affimed Therapeutics' Data Will Finally Trump Execution In 2018

via: SeekingAlpha at 2018-02-01 16:15:49:000

Shares of German biotech firm Affimed Therapeutics ( AFMD ) have lost close to 70% of their value over the past three years and been a serial disappointment to investors. As I 'm looking at the ticker now it 's traded over 20 times average daily volume and appears to be filling the recent g… read more...

Midday Gainers / Losers (2/1/2018)

via: SeekingAlpha at 2018-02-01 12:50:05:000

Gainers: AFMD +40% . QNST +36% . RVLT +31% . LQDT +27% . CMPR +18% . BSPM +18% . OTEX +17% . ACMR +15% . ZN +15% . EBAY +14% . More news on: Affimed Therapeutics, QuinStreet, Inc., Revolution Lighting Technologies, Inc., Stocks on the move, Read more ….. read more...

Midday Gainers / Losers (2/1/2018)

via: SeekingAlpha at 2018-02-01 12:50:05:000

Gainers: AFMD +40% . QNST +36% . RVLT +31% . LQDT +27% . CMPR +18% . BSPM +18% . OTEX +17% . ACMR +15% . ZN +15% . EBAY +14% . More news on: Affimed Therapeutics, QuinStreet, Inc., Revolution Lighting Technologies, Inc., Stocks on the move, Read more ….. read more...

Midday Gainers / Losers (2/1/2018)

via: SeekingAlpha at 2018-02-01 12:50:05:000

Gainers: AFMD +40% . QNST +36% . RVLT +31% . LQDT +27% . CMPR +18% . BSPM +18% . OTEX +17% . ACMR +15% . ZN +15% . EBAY +14% . More news on: Affimed Therapeutics, QuinStreet, Inc., Revolution Lighting Technologies, Inc., Stocks on the move, Read more ….. read more...

Updated data on Affimed's AFM13 shows 89% response rate in HL patients; shares up 28%

via: SeekingAlpha at 2018-02-01 10:10:00:000

Thinly traded nano cap Affimed N.V. ( AFMD +28.3% ) is up on a 7x surge in volume on the heels of its announcement of updated data from two clinical trials evaluating lead candidate AFM13 in patients with Hodgkin lymphoma (HL). More news on: Affimed Therapeutics, Merck & Co Inc., H… read more...

Updated data on Affimed's AFM13 shows 89% response rate in HL patients; shares up 28%

via: SeekingAlpha at 2018-02-01 10:10:00:000

Thinly traded nano cap Affimed N.V. ( AFMD +28.3% ) is up on a 7x surge in volume on the heels of its announcement of updated data from two clinical trials evaluating lead candidate AFM13 in patients with Hodgkin lymphoma (HL). More news on: Affimed Therapeutics, Merck & Co Inc., H… read more...

Updated data on Affimed's AFM13 shows 89% response rate in HL patients; shares up 28%

via: SeekingAlpha at 2018-02-01 10:10:00:000

Thinly traded nano cap Affimed N.V. ( AFMD +28.3% ) is up on a 7x surge in volume on the heels of its announcement of updated data from two clinical trials evaluating lead candidate AFM13 in patients with Hodgkin lymphoma (HL). More news on: Affimed Therapeutics, Merck & Co Inc., H… read more...

Premarket Gainers as of 9:05 am (02/01/2018)

via: SeekingAlpha at 2018-02-01 09:18:54:000

AFMD +28% . More news on: Affimed Therapeutics, OpGen, Lightbridge Corp, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (02/01/2018)

via: SeekingAlpha at 2018-02-01 09:18:54:000

AFMD +28% . More news on: Affimed Therapeutics, OpGen, Lightbridge Corp, Stocks on the move, Read more … read more...

Premarket Gainers as of 9:05 am (02/01/2018)

via: SeekingAlpha at 2018-02-01 09:18:54:000

AFMD +28% . More news on: Affimed Therapeutics, OpGen, Lightbridge Corp, Stocks on the move, Read more … read more...

Affimed's lead candidate shows treatment benefit in early-stage study; investors unimpressed, shares down 27%

via: SeekingAlpha at 2017-12-11 13:35:41:000

Thinly traded nano cap Affimed N.V. ( AFMD -26.9% ) slumps on more than a 4x surge in volume on the heels of its announcement of interim results from a Phase 1b clinical trial assessing lead candidate AFM13 combined with Merck's KEYTRUDA (pembrolizumab) in patients with relapsed/refrac… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2017-12-11 12:47:35:000

Gainers: YTEN +215% . DAVE +32% . NETE +32% . SSC +24% . BPMC +23% . BLUE +23% . OSTK +21% . CLSD +21% . GROW +19% . RIOT +19% . More news on: Yield10 Bioscience, Inc., Famous Dave's of America, Inc., Net Element International, Inc., Stocks on the move, … read more...

Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-07 15:23:06:000

Affimed Therapeutics (AFMD) Q3 2017 Results Earnings Conference Call November 07, 2017, 8:30 AM ET Executives Anca Alexandru Head-Communications Adi Hoess Chief Executive Officer Florian Fischer Chief Financial Officer Analysts Yale Jen L… read more...

Affimed Therapeutics 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-11-07 10:05:49:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2017 Q3 earnings Read more … read more...

Affimed reports Q3 results

via: SeekingAlpha at 2017-11-07 07:34:03:000

Affimed (NASDAQ: AFMD ): Q3 EPS of -0.18 More news on: Affimed Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2017-11-06 17:30:37:000

AAWW , AFMD , AGEN , ALLT , ASIX , ATHM , ATRO , ATRS , BCRX , BLD , CBM , CBOE , CCE , CRIS , CROX , DEA , DF , DNR , EMR , EXPD , GLDD , HAE , HAIN , HCN , HL , HLNE , IONS , JELD , LABL , LGIH , LNCE , LXP , MTRX , MZOR , NS , ONCE , PNK , PRIM , RC… read more...

Affimed (AFMD) Presents At LEERINK Partners Roundtable Series On Rare Disease And Immuno-Oncology - Slideshow

via: SeekingAlpha at 2017-09-29 11:55:03:000

The following slide deck was published by Affimed Therapeutics in conjunction with this Read more … read more...

Affimed N.V. (AFMD) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-09-08 12:44:14:000

The following slide deck was published by Affimed Therapeutics in conjunction with this Read more … read more...

Affimed Therapeutics' (AFMD) CEO Adi Hoess on Q2 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-08-01 16:47:07:000

Affimed Therapeutics (AFMD) Q2 2017 Earnings Conference Call August 1, 2017 8:30 AM ET Executives Anca Alexandru Head of Communications Adi Hoess Chief Executive Officer Florian Fischer Chief Financial Officer Analysts Maury Raycroft Jeff… read more...

Affimed Therapeutics 2017 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-08-01 09:59:45:000

The following slide deck was published by Affimed Therapeutics in conjunction with their 2017 Q2 earnings Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX